Inari Medical Stock Price, News & Analysis (NASDAQ:NARI)

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings or view top-rated stocks.

5 analysts have issued 1 year price targets for Inari Medical's shares. Their NARI share price targets range from $65.00 to $100.00. On average, they predict the company's share price to reach $82.00 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price.
View analysts price targets for NARI or view top-rated stocks among Wall Street analysts.

Inari Medical's stock was trading at $63.56 at the beginning of the year. Since then, NARI stock has decreased by 2.2% and is now trading at $62.15.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our NARI earnings forecast.

Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Wednesday, November, 1st. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.00 by $0.05. The firm earned $126.37 million during the quarter, compared to analysts' expectations of $121.92 million. Inari Medical had a negative trailing twelve-month return on equity of 0.64% and a negative net margin of 0.59%. The business's revenue was up 31.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.19) EPS.

ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Principal Healthcare Innovators ETF (BTEC) and IQ Healthy Hearts ETF (HART).iShares U.S. Medical Devices ETF (IHI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

(NARI) raised $110 million in an IPO on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Inari Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.85%), Brown Advisory Inc. (2.52%), JPMorgan Chase & Co. (2.35%), Morgan Stanley (1.57%), Allspring Global Investments Holdings LLC (1.31%) and Northern Trust Corp (1.14%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Gilde Healthcare Cooperatieve, Kirk G Nielsen, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends.

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.